Histone 2 mutations have been reported in pancreatic cancer, glioblastoma, prostate cancer, and lung cancer.52 Zhao and Dai53 (2021) reported that HIST3H2A might regulate the progression of tumor immunity in pancreatic cancer by modulating the JAK-STAT pathway.53 This evidence concerns the gene H2AC25 and prostate carcinoma.